CrystalGenomics

We strive to be a global biopharma leader whose mission is

to develop innovative, life-changing medicine

Pipeline

CG-652
  • Indication
    Rheumatoid arthritis
  • Development stage
    Phase 1 clinical study in progress
  • Mechanism of action and features
    • Effective suppression of pain and inflammation in rheumatic diseases
    • Confirmation of synergistic effect when two drugs are used in combination in non-clinical experiments
    • Oral combination drug under development

CG-652